We demonstrate that comparative genomic hybridization (CGH) onto cDNA microarrays may be used to carry out genome-wide screens for regions of genetic loss, including homozygous (complete) deletions that may represent the possible location of tumour suppressor genes in human cancer. Screening of the prostate cancer cell lines LNCaP, PC3 and DU145 allowed the mapping of specific regions where genome copy number appeared altered and led to the identification of two novel regions of complete loss at 17q21.31 (500 kb spanning STAT3) and at 10q23.1 (50-350 kb spanning SFTPA2) in the PC3 cell line.
We demonstrate that comparative genomic hybridization (CGH) onto cDNA microarrays may be used to carry out genome-wide screens for regions of genetic loss, including homozygous (complete) deletions that may represent the possible location of tumour suppressor genes in human cancer. Screening of the prostate cancer cell lines LNCaP, PC3 and DU145 allowed the mapping of specific regions where genome copy number appeared altered and led to the identification of two novel regions of complete loss at 17q21.31 (500 kb spanning STAT3) and at 10q23.1 (50-350 kb spanning SFTPA2) in the PC3 cell line. Oncogene (2003 Oncogene ( ) 22, 1247 Oncogene ( -1252 Oncogene ( . doi:10.1038 Sites of complete genomic loss in human cancer have generated considerable interest, because they frequently flag the location of tumour suppressor genes. The suppressor genes DPC4/SMAD4, RB1, TP53, PTEN and p16INK4a-p14ARF can all be inactivated by deletions in which loss of the chromosome containing one copy of the gene is accompanied by a deletion within or spanning the remaining gene copy. Indeed, most of these suppressor genes (DPC4/SMAD4, RB1, PTEN, p16INK4a) were originally pinpointed through mapping regions of complete loss in cancer cells (Friend et al., 1986; Kamb et al., 1994; Hahn et al., 1996; Li et al., 1997) . A recent example is the RASSF1 gene, which was identified as a candidate lung cancer suppressor gene within a 120 kb minimal homozygous deletion at 3p21.31 (Dammann et al., 2000) .
Caution must be exercised in interpreting the presence of homozygous losses because they may also arise at fragile sites within the human genome or may reflect random loss occurring as a consequence of genome instability in cancer cells. However, even regions of loss at fragile sites have been proposed as locations for human tumour suppressor genes (Sozzi et al., 1996; Bednarek et al., 2001) . Despite this caveat, the mapping of homozygous losses has provided valuable clues in the hunt for novel tumour suppressor genes when considered together with other types of mapping data such as loss of chromosome heterozygosity (LOH) and information from chromosome transfer experiments.
Conventionally, homozygous loss has been assessed by Southern blotting and PCR-based approaches. More recently Pinkel et al. (1998) , Snijders et al. (2001) and Cai et al. (2002) have demonstrated that comparative genomic hybridization (CGH) onto microarrayed bacterial artificial chromosome (BAC) and Pl artificial chromosome (PAC) clones may be used to map high level amplification, low copy number gains and complete genetic loss. CGH onto cDNA microarrays has also been used to map amplification events (Pollack et al., 1999; Monni et al., 2001; Clark et al., 2002) , and in the current study we demonstrate that this technology may also be used to monitor regions of single-copy loss and complete gene loss in human cancer.
CGH experiments have been carried out on a 'geneset' cDNA microarray of 5603 known cDNA sequences. Although the clones were not selected on the basis of their chromosome location, this represents an average of one clone every 570 kb throughout the genome. We have previously established that CGH onto this microarray can be used to detect chromosome gains (Clark et al., 2002) . To test our ability to measure single-copy loss, we carried out CGH in which male DNA (XY, labelled with Cy3-dCTP) and female DNA (XX, labelled with Cy5-dCTP) were cohybridized to cDNA microarrays ( Figure 1a , replicate hybridizations are represented in red and blue). The average log 2 Cy5 : Cy3 hybridization ratio for X-chromosome genes was 0.35, which compares to an ideal log 2 value of 1 for a 2 : 1 female to male X chromosome ratio and a ratio of 0.72 obtained by Snijders et al. (2001) using BAC microarrays.
Since some variability in the Cy5 : Cy3 ratios is observed for both autosomal and for X chromosome cDNAs, we have subjected the CGH microarray data to formal statistical analysis. For detection of abnormal regions, we first constructed a quadratic Lowess curve (Cleveland, 1979; Cleveland and Devlin, 1988) , which can be viewed as a locally weighted polynomial regression curve through each data set. We then identified those regions in which contiguous segments of the Lowess curve were consistently greater than (or less than) 0.5 standard deviations away from the mean of the data points. Having located these regions of interest, we used the Mann-Whitney U test to determine whether each selected region differed significantly from the set of data points from regions that had not been selected for examination by this test.
When these analyses were performed on the male (XY) against female (XX) CGH data, the test selected the X-chromosome genes as a separate group and demonstrated that the distribution of ratios observed for X chromosome genes is highly significantly different from the distribution of ratios observed for autosomal genes (Po10 À15 in each of four independent experiments). These results demonstrate that when data from CGH studies onto cDNA microarrays are examined using this statistical test, regions of single-copy chromosomal loss are identified with a high degree of statistical certainty.
The examination of two cDNAs (DAZ and TSPYQ1) mapping to the Y chromosome outside the pseudoautosomal region demonstrated that complete loss of gene sequences can also be detected. Each of these clones exhibited log 2 hybridization ratios that were substantially different from those observed for autosomal sequences (Av ¼ À2.19, Figure 1a) .
CGH onto cDNA microarray was used to monitor chromosome gains and losses in the prostate cancer cell lines PC3, DU145 and LNCaP (Figure 1b-d) . When the statistical test described above was applied to these data, many regions of gain and loss were detected with a high degree of statistical certainty: those regions where Po0.0001 are marked in the lower panels of Figure  1b -d. Furthermore, the profile of gains and losses were highly reproducible in duplicate experiments and are quite distinct in the different cell lines. The regions of chromosome gain included 8q22-24 and 10q11.22-q22 in PC3 cells as well as 1q21.3-q31, 5p and 14q13-21 in DU145 cells. Regions of low copy number chromosomal loss included: 6q16-qter, pter-12p12, pter-16q13 and chromosomes 13 and 22 in PC3 cells; 4q31-qter and chromosome 13 in DU145 cells; and chromosome 2 and 19q13.2-13.3 in LNCaP cells. The majority of these alterations were also detected in conventional CGH studies of these cell lines (Aurich-Costa et al., 2001) . The only alteration that appeared common to all three cell lines was the loss of 6q16-qter corresponding figure (a-d) , the lower panel shows the quadratic Lowess curves (Cleveland, 1979; Cleveland and Devlin, 1988) through each data set, with the data from each chromosome examined individually. The corresponding red and blue bars above and below the Lowess curves highlight those regions indicated by the Mann-Whitney U test to have a statistically distinct distribution at a significance level of Po0.0001. The LNCaP, PC3 and DU145 prostate carcinoma cell lines, kindly provided by Professor Norman Maitland (University of York) were grown in DMEM supplemented with foetal calf serum (10% v/v). All other methods including the preparation of genomic DNA, the construction of the 5603 cDNA geneset microarray, labelling with fluorescent probes, Southern blotting, hybridization of probes to the microarray, image collection and data analyses were carried out essentially as described previously (Clark et al., 2002) . Most of the cDNA clones were in the size range of 500 bp-2 kb. The cDNA clones are positioned randomly on the microarray and are not positioned according to their chromosome position. Data for these analyses are presented without subtraction of backgrounds. This practice can underestimate the hybridization ratio, but has the advantage that it avoids the random scatter that can be generated when background values are subtracted from faintly hybridizing spots (Yang et al., 2001) . However, statistical analyses were performed on three data sets: (i) no subtraction of background; (ii) subtraction of background; and (iii) subtraction of background with data points having low foreground/background ratio (e.g., o1.4, as used by Nielsen et al., 2002) removed. For example, the data for the X-chromosome cDNAs in four replicate male vs female CGH hybridizations were shown by the Mann-Whitney U test to have a distribution distinct from autosomal sequences at a significance of Po10 , when analysed by each of the three different ways described above. Statistical identification of outliers was performed as previously described (Heiskanen et al., 2000; Clark et al., 2002) . Genes on the graphs are ordered on their megabase distance from the telomere of the p arm of each chromosome. These values were obtained from the December 2001 data-freeze UCSC Human Genome Map (http://genome.ucsc.edu). Red arrows indicate the positions of the candidate deleted regions. The complete data set is available at http://www.icr.ac.uk/clark to a region of deletion in prostate cancer recently mapped by Hyytinen et al. (2002) .
Clones that exhibited a log 2 hybridization ratio of oÀ1 and that were flagged in duplicate hybridizations when the statistical outlier test (Clark et al., 2002) was carried out at high stringency (P ¼ 0.001) were considered as candidate completely deleted genes. In these tests, six candidate genes were identified from five separate chromosomal regions (red arrows in Figure 1) . Complete genetic loss was tested by hybridizing the gene probes to Southern blots of prostate cancer cell line DNAs (Figure 2 ) revealing that five of the flagged genes were homozygously deleted. PGA (pepsinogen A) at 11q13.3 was the only gene examined that exhibited partial loss (Figure 2) . Since DU145 is a near triploid cell line (Aurich-Costa et al., 2001 ) that contains three copies of chromosome 11, the observed result (Figure 2 ) may correspond to loss of two of the three copies of the PGA gene in this cell line. All of the autosomal regions of complete loss were within the PC3 cell line, including two genes (STAT5B, GCNL2) at 17q21.31, the SFTPA2 gene at 10q23.1, and the KIAA0416 gene at 5q31.2. Genes flanking the SFTPA2 gene appear to be overrepresented suggesting that this deletion preceded an increase in copy number at this locus. The KIAA0416 gene lies within an intron of the alpha catenin gene, which was previously reported by Morton et al. (1993) to be homozygously deleted at its 5 0 end in PC3 cells. In PC3 cells, the chromosome clones DAZ and TSPYQ1 exhibited log 2 hybridization ratios of oÀ1 (Figure 1) consistent with the reported loss of the Y chromosome in this cell line (Aurich-Costa et al., 2001) (Figure 2) .
Maps of the two novel regions of complete loss at 17q21.31 and 10q23.1 detected in PC3 cells are shown in Figure 3 . The same general region of chromosome 17 was identified as the location of a prostate cancer suppressor gene in chromosome transfer studies (Chekmareva et al., 1997) and of LOH in primary human prostate cancer (Uchida et al., 1999) . The protein encoded by the STAT3 gene in the deleted region is a signal transduction protein in the JAK/STAT pathway that when activated can demonstrate proapoptotic and growth-inhibiting roles in a variety of cell types (Minami et al., 1996; Nakajima et al., 1996; Chapman et al., 1999; Bromberg, 2001) . Spiotto and Chung (2000a) report that PC3 cells do not express STAT3 and have shown that re-expression of STAT3 in PC3 activates the STAT3 pathway, slows growth and induces neuroendocrine differentiation. Spiotto and Chung (2000b) also provide evidence that the STAT3 protein is expressed but is functionally inactive as a transcription factor in both TSU and DU145 prostate carcinoma cell lines. When considered together, these observations raise the intriguing possibility that STAT3 may have a tumour suppressor function in some prostate cancers. The SFTPA1 and SFTPA2 genes within the chromosome 10 deletion encode products that combine to form the lung surfactant SP-A (Khubchandani and Snyder, 2001). SP-A has been detected in several tissues including the gastrointestinal Figure 3 Genome maps for regions of complete deletion at (a) 17q21.31 and (b) 10q23.1 in prostate cancer PC3 cells. Maps were generated using Human Genome Mapping data available at the Ensembl (http://www.ensembl.org/Homo_Sapiens/contigview) web site (Feb 2002 data-freeze). Confirmation of presence or loss of genes within each region was achieved either by PCR-based mapping or by Southern blot hybridization. For example, mapping of loss within the chromosome 10 region demonstrated that SFTPA1 and SFTPA2 were deleted, but that the flanking genes PPIF and Q9NQE0 were not tract and the prostate, and has been proposed to have a role in innate immune response (Khubchandani and Snyder, 2001 ). The SFTPA1 and SFTPA2 genes located at map position 89 Mb are flanked by two genes that have already been proposed as prostate cancer suppressor genes: the PTEN gene at 93 Mb and the ANX7 gene at 78 Mb (Li et al., 1997; Srivastava et al., 2001) .
CGH onto cDNA microarrays has been used in several studies for genome-wide screening of amplification events in human cancer (Pollack et al., 1999; Forozan et al., 2000; Clark et al., 2002) . We have now shown that data obtained in such studies can, when subject to statistical analysis, be used in a similar fashion to conventional CGH to map regions of low copy number chromosome loss. However, the approach presented here has the advantage that losses are mapped by their gene position rather than chromosomal band and the analysis can immediately provide a list of candidate genes that occur within the region of interest. More importantly the same analysis can be used to map regions of homozygous loss in human cancer, potentially at a considerably higher resolution than CGH studies onto PAC/BAC microarrays, where the resolution is limited by the larger size of the PACs or BACs (120-200 kb) . Since the size of the cDNA clones on the microarray is in the range 500 bp-2 kb, CGH onto cDNA microarrays could potentially detect small complete deletions spanning single gene or exons, such as those that can inactivate the p16INK4a gene (England et al., 1996) that would not be detected in similar studies on BAC/PAC microarrays. In future studies, we are planning (i) to increase the number of cDNA clones on the microarray to improve further the resolution of this method and (ii) to examine the significance of the regions of total loss that we have detected in prostate cancer.
